Aliases & Classifications for Pancytopenia

MalaCards integrated aliases for Pancytopenia:

Name: Pancytopenia 12 29 54 6 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:12450
ICD9CM 34 284.1
NCIt 49 C34889
SNOMED-CT 67 127034005
ICD10 32 D61.81
UMLS 71 C0030312

Summaries for Pancytopenia

Disease Ontology : 12 An anemia that is characterized by a reduction in the number of red blood cells, white blood cells, and platelets.

MalaCards based summary : Pancytopenia is related to amegakaryocytic thrombocytopenia, congenital and langerhans cell histiocytosis. An important gene associated with Pancytopenia is DNAJC21 (DnaJ Heat Shock Protein Family (Hsp40) Member C21), and among its related pathways/superpathways are JAK-STAT signaling pathway and Folate Metabolism. The drugs Prednisone and Oprelvekin have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are homeostasis/metabolism and hematopoietic system

Wikipedia : 74 Pancytopenia is a medical condition in which there is a reduction in the number of red and white blood... more...

Related Diseases for Pancytopenia

Diseases related to Pancytopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 760)
# Related Disease Score Top Affiliating Genes
1 amegakaryocytic thrombocytopenia, congenital 33.5 THPO MPL DKC1
2 langerhans cell histiocytosis 33.3 IFNG CSF2 CSF1
3 diamond-blackfan anemia 32.8 TP53 THPO TERT MPL EPO DNAJC21
4 aplastic anemia 32.7 TPMT TP53 THPO TERT SH2D1A MPL
5 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 31.7 TTR FOXP3 EPO CSF3
6 thrombocytopenia 31.6 THPO TERT MPL MGMT IFNG FOXP3
7 exanthem 31.6 IFNG CSF3 CSF2
8 miliary tuberculosis 31.5 IFNG EPO CSF3
9 hypersplenism 31.5 THPO IFNG FOXP3 EPO CSF3 CSF2
10 neutropenia 31.5 TPMT TP53 THPO MPL IFNG EPO
11 granulocytopenia 31.5 CSF3 CSF2 CP
12 myelofibrosis 31.5 TP53 THPO MPL EPO CSF3
13 hemoglobinuria 31.3 THPO MPL EPO CSF3
14 myelodysplastic syndrome 31.3 TP53 THPO TERT SAMD9L MPL MGMT
15 acute leukemia 31.3 TPMT THPO MPL EPO CSF3 CSF2
16 iron metabolism disease 31.3 TTR EPO CP
17 leukemia, acute lymphoblastic 31.3 TPMT TP53 THPO MPL DHFR CSF3
18 purpura 31.3 THPO MPL IFNG
19 dyskeratosis congenita 31.2 TP53 TERT EPO DNAJC21 DKC1 CSF3
20 acquired immunodeficiency syndrome 31.2 TP53 IFNG EPO CSF2
21 rheumatoid arthritis 31.2 TTR SH2D1A IFNG FOXP3 CSF2 CSF1
22 refractory anemia 31.1 MPL EPO CSF3
23 arthritis 31.1 IFNG FOXP3 CSF2 CSF1 CPT2
24 aspergillosis 31.1 IFNG CSF3 CSF2 CSF1
25 malaria 31.0 TTR TP53 IFNG FOXP3 EPO DHFR
26 iron deficiency anemia 31.0 THPO EPO CP
27 thrombocytopenia due to platelet alloimmunization 31.0 THPO MPL FOXP3
28 thrombocytosis 30.9 THPO MPL EPO CSF3 CSF2
29 polycythemia 30.9 THPO MPL EPO
30 shwachman-diamond syndrome 1 30.9 TP53 DNAJC21 DKC1 CSF3
31 stomatitis 30.9 IFNG CSF3 CSF2
32 myeloma, multiple 30.9 TTR TP53 IFNG FOXP3 EPO CSF3
33 acute radiation syndrome 30.8 EPO CSF3
34 diarrhea 30.8 TTR IFNG FOXP3 CSF3
35 leukemia, acute myeloid 30.8 TP53 THPO TERT SAMD9L MPL IFNG
36 pneumonia 30.8 TTR IFNG FOXP3 DHFR CSF3 CSF2
37 polycythemia vera 30.8 THPO MPL EPO CSF3 CSF2
38 leukemia, chronic myeloid 30.8 TP53 THPO MPL EPO CSF3 CSF2
39 severe combined immunodeficiency 30.7 IFNG DKC1 CSF3 CSF2 CSF1
40 acute promyelocytic leukemia 30.7 TP53 THPO TERT CSF3 CSF2 CSF1
41 omenn syndrome 30.7 SH2D1A IFNG FOXP3 CSF1
42 gastroenteritis 30.7 IFNG CSF3 CSF2 CP
43 peripheral nervous system disease 30.7 TTR TP53 IFNG EPO CSF3
44 lung disease 30.7 TP53 TERT IFNG CSF3 CSF2
45 granulosa cell tumor of the ovary 30.6 TP53 TERT CP
46 glioblastoma multiforme 30.6 TP53 TERT MGMT IFNG FOXP3 CSF3
47 monocytic leukemia 30.6 IFNG CSF2 CSF1
48 mucormycosis 30.6 IFNG CSF3 CSF2
49 myeloproliferative neoplasm 30.5 THPO MPL EPO CSF3 CSF2
50 cyclic neutropenia 30.5 IFNG CSF3 CSF2 CSF1

Graphical network of the top 20 diseases related to Pancytopenia:



Diseases related to Pancytopenia

Symptoms & Phenotypes for Pancytopenia

MGI Mouse Phenotypes related to Pancytopenia:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 CP CPT2 CSF1 CSF2 DHFR DKC1
2 hematopoietic system MP:0005397 10.36 CP CSF1 CSF2 CSF3 DHFR DKC1
3 immune system MP:0005387 10.31 CP CPT2 CSF1 CSF2 CSF3 DHFR
4 cellular MP:0005384 10.26 CP CSF1 CSF2 DHFR DKC1 EPO
5 cardiovascular system MP:0005385 10.19 CP CPT2 CSF1 CSF2 DHFR EPO
6 mortality/aging MP:0010768 10.13 CPT2 CSF1 CSF2 DHFR DKC1 DNAJC21
7 integument MP:0010771 10.07 CSF1 CSF2 CSF3 DHFR DKC1 EPO
8 liver/biliary system MP:0005370 9.92 CP CSF1 DHFR EPO FOXP3 IFNG
9 neoplasm MP:0002006 9.7 CSF2 DKC1 IFNG MGMT SAMD9L TERT
10 no phenotypic analysis MP:0003012 9.5 CSF1 DKC1 FOXP3 IFNG MGMT TP53
11 respiratory system MP:0005388 9.32 CPT2 CSF1 CSF2 DKC1 EPO FOXP3

Drugs & Therapeutics for Pancytopenia

Drugs for Pancytopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Oprelvekin Approved, Investigational Phase 4 145941-26-0
3
Nandrolone decanoate Approved, Illicit Phase 3 360-70-3 9677
4
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 3 62-90-8 229455
5
Vidarabine Approved, Investigational Phase 2, Phase 3 24356-66-9 21704 32326
6
Nandrolone Experimental, Investigational Phase 3 434-22-0 9904
7 Thymoglobulin Phase 3
8 Hormones Phase 3
9 Hormone Antagonists Phase 3
10 Anabolic Agents Phase 3
11 Androgens Phase 3
12 Cyclosporins Phase 2, Phase 3
13
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
15
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
16
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
17
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
18
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
19 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
20
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
21
Idarubicin Approved Phase 2 58957-92-9 42890
22
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 6253
23
Danazol Approved Phase 1, Phase 2 17230-88-5 28417
24
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
25
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
26
Abatacept Approved Phase 1, Phase 2 332348-12-6 10237
27
Hydroxyurea Approved Phase 1, Phase 2 127-07-1 3657
28
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
29
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
30
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
31
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
32
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
33
Busulfan Approved, Investigational Phase 2 55-98-1 2478
34
tannic acid Approved Phase 2 1401-55-4
35
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
36
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
37
Mycophenolic acid Approved Phase 2 24280-93-1 446541
38
Melphalan Approved Phase 1, Phase 2 148-82-3 460612 4053
39
Mesna Approved, Investigational Phase 2 3375-50-6 598
40
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
41
alemtuzumab Approved, Investigational Phase 2 216503-57-0
42
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
43
Lenograstim Approved, Investigational Phase 2 135968-09-1
44
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
45
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
46
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
47
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
48
Iron Approved, Experimental Phase 2 15438-31-0, 7439-89-6 27284 23925
49
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
50
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7

Interventional clinical trials:

(show top 50) (show all 122)
# Name Status NCT ID Phase Drugs
1 Different Doses of Anti-thymocyte Globin With 2.5 or 3.75mg/kg to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4 ATG
2 Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia Completed NCT02314273 Phase 4 rhIL-11
3 Randomized Clinical Trial of the Use of Eltrombopag in Children With Idiopathic Aplastic Anemia Recruiting NCT03243656 Phase 4 Eltrombopag
4 Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Selected Non-Malignant Diseases Unknown status NCT01019876 Phase 2, Phase 3 Fludarabine;Cyclophosphamide;Cyclophosphamide 40;Cyclophosphamide 30
5 The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population Unknown status NCT02393508 Phase 3
6 Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders Completed NCT00000597 Phase 3 antilymphocyte serum;nandrolone
7 Bone Marrow Transplantation for Non-Malignant Congenital Bone Marrow Failure Disorders Completed NCT00176878 Phase 2, Phase 3 Fludarabine monophosphate;Busulfan
8 Randomized Comparison of Cyclophosphamide Versus Cyclophosphamide Plus Fludarabine In Addition To Anti-Thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Bone Marrow Failure Syndrome Completed NCT00774527 Phase 3 Cyclophosphamide-fludarabine-anti thymocyte globulin
9 Outcome of Peripheral Blood Allogenic Stem Cell Transplantation Using Non-anti Thymocyte Globulin (ATG ) Conditioning Regimens in Severe Aplastic Anemia Patients Not yet recruiting NCT03295058 Phase 2, Phase 3 Non ATG Conditioning regimen;GVHD Prophylaxis;ATG conditioning regimen
10 Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) Unknown status NCT01760096 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
11 Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria Unknown status NCT01642979 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
12 A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia Unknown status NCT02203396 Phase 2 rabbit ATG, Cyclosporine, Levamisole
13 Male Hormones for Telomere Related Diseases Unknown status NCT02055456 Phase 1, Phase 2 Nandrolone Decanoate
14 PhaseⅠ/ⅡTrial of Bone Marrow Derived Mesenchymal Stem Cell Transplantation From Related Donor to Patients With Relapsed/Refractory Aplastic Anemia. Unknown status NCT01305694 Phase 1, Phase 2
15 Using Daily Self-administered Indirect Moxibustion to Zusanli St-36 to Reduce Chemotherapy Induced Pancytopenia: a Feasibility Study Unknown status NCT02781155 Phase 1, Phase 2
16 PhaseⅡTrial of Co-transplantation With Bone Marrow Derived Mesenchymal Stem Cells From Related Donors in Alternative Donor Transplantation of Severe Aplastic Anemia. Unknown status NCT02247973 Phase 2
17 Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation Unknown status NCT01757145 Phase 2 Eltrombopag
18 A Randomized Trial of Immunosuppression in Aplastic Anemia Patients With Refractory Pancytopenia or Suboptimal Hematologic Response After h-ATG/CsA Treatment Completed NCT00065260 Phase 2 Campath-1H;r-ATG;CsA
19 A Randomized Study of Three Immunosuppressive Regimens in Treatment Naive Patients With Severe Aplastic Anemia: Horse ATG/CsA Taper vs Rabbit-ATG/CsA vs Alemtuzumab Completed NCT00260689 Phase 2 Cyclosporine;Alemtuzumab
20 Doxil® (Pegylated Liposomal Doxorubicin), Dexamethasone Plus Thalidomide (Ddt) in Previously Untreated Multiple Myeloma: A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life Completed NCT00222105 Phase 2 Doxil;Thalidomide;Dexamethasone
21 A Randomized Trial of a Novel Immunosuppressive Combination of ATG, CsA and Sirolimus (Rapamune) vs a Slow Taper Cyclosporine Regimen in Subjects With Severe Aplastic Anemia Completed NCT00061360 Phase 2 ATG+Rapamune+cyclosporine;ATG+cyclosporine
22 Phase I/II Study of Reduced Intensity Conditioning for Patients With Non-Malignant Diseases Using CD3+/CD19+ Depleted Unrelated Donor or Partially Matched Related Donor Peripheral Stem Cells Completed NCT02277639 Phase 2
23 Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia Completed NCT01193283 Phase 1, Phase 2 Cyclophosphamide;Cyclosporine
24 A Non-randomized, Phase II Study of Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A (ATG/CsA) in Subjects With Moderate or More Severe Aplastic Anemia Who Have Not Received Prior ATG/Anti-lymphocyte Globulin (ALG)-Based Immunosuppressive Therapy Completed NCT02404025 Phase 2 Eltrombopag;Rabbit ATG;CsA
25 Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes Completed NCT00004143 Phase 2 Campath, Chemo and/or TBI Allo SCT
26 HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR PATIENTS WITH BONE MARROW FAILURE SYNDROME - A PHASE 2 STUDY Completed NCT00731328 Phase 2
27 A Non-randomized, Open-label, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia Completed NCT02148133 Phase 2 Eltrombopag 12.5 mg;Eltrombopag 25 mg
28 Transfusion of CD45RA-depleted Donor Lymphocytes to Improve Regeneration of Antimicrobial Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation Completed NCT02337595 Phase 1, Phase 2
29 Sirolimus for Patients With Chronic and/or Refractory Autoimmune Cytopenias: A Pilot Series Completed NCT00392951 Phase 1, Phase 2 sirolimus
30 CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease Completed NCT01049854 Phase 2 Full Intensity with TBI;Full Intensity;Reduced Intensity;Reduced Intensity (Fanconi)
31 Idarubicin and Ara-C in Combination With Gemtuzumab-Ozogamicin (IAGO) for Young Untreated Patients, Without an HLA Identical Sibling, With High Risk MDS or AML Developing After a Preceding Period With MDS During 6 Months Duration: A Phase II Study Completed NCT00077116 Phase 2 busulfan;cyclophosphamide;cytarabine;gemtuzumab ozogamicin;idarubicin
32 A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia Completed NCT02302469 Phase 1, Phase 2 Revlimid
33 A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia Completed NCT01187017 Phase 1, Phase 2 Cyclophosphamide;Fludarabine
34 A Randomized Trial for the Treatment of Relapsing Aplastic Anemia With Mycophenolate Mofetil (MMF) and Cyclosporine (CSA) Completed NCT00005935 Phase 2 Mycophenolate mofetil;Cyclosporine
35 A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS) Completed NCT00072969 Phase 2 Daclizumab
36 Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment Completed NCT00944749 Phase 2 h-ATG (ATGAM );Cyclosporine (Gengraf )
37 A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome (MDS) Completed NCT00217594 Phase 2 Alemtuzumab (Campath)
38 Male Hormones for Telomere Related Diseases Completed NCT01441037 Phase 1, Phase 2 Danazol
39 Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301) Completed NCT00326417 Phase 1, Phase 2 Fludarabine;Cyclophosphamide 150mg;Cyclophosphamide 100mg;Cyclophosphamide 50mg
40 AMD3100 in Combination With G-CSF to Mobilize Peripheral Blood Stem Cells in Patients With Fanconi Anemia(FA): A Phase I/II Study Completed NCT00479115 Phase 1, Phase 2 AMD3100
41 A Phase II Trial of Non-Myeloablative (NMA) Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Donor (MUD) Bone Marrow for Newly Diagnosed Patients With Severe Aplastic Anemia Recruiting NCT02833805 Phase 2 Thymoglobulin;Fludarabine;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
42 A Phase I/II Trial of Reduced Intensity Conditioning and Familial HLA-Mismatched Bone Marrow Transplantation in Children With Non-Malignant Disorders Recruiting NCT03128996 Phase 1, Phase 2 RIC regimen;GVHD prophylaxis regimen
43 Lung Transplant in Tandem With Bone Marrow Transplant for Combined Lung and Bone Marrow Failure Recruiting NCT03500731 Phase 1, Phase 2 Rituximab;Alemtuzumab;Fludarabine;Thiotepa;G-CSF;Hydroxyurea
44 PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders Recruiting NCT03513328 Phase 1, Phase 2 Thiotepa--single daily dose;Thiotepa--escalated dose
45 A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor Recruiting NCT02828592 Phase 2 Fludarabine;Cyclophosphamide;Rabbit ATG;Cyclophosphamide
46 Pre-emptive Therapy With Low-dose Decitabine for Patients With Decreased Donor Chimerism After Allogeneic Stem Cell Transplantation Recruiting NCT03663751 Phase 2 Decitabine
47 Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases Recruiting NCT03314974 Phase 2
48 Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen Recruiting NCT02722668 Phase 2 Fludarabine;Cyclophosphamide;MMF;Sirolimus
49 Anti-Viral Central Memory CD8 Veto Cells in Haploidentical Hematopoietic Stem Cell Transplantation Recruiting NCT03622788 Phase 1, Phase 2 Cyclophosphamide;Fludarabine
50 Pilot Study Assessing the Feasibility of CD34+ Cells Mobilization and Collection After Treatment With G-CSF and Plerixafor in Patients With Fanconi Anemia for Subsequent Treatment by Gene Therapy Recruiting NCT02678533 Phase 1, Phase 2 G-CSF;Plerixafor

Search NIH Clinical Center for Pancytopenia

Genetic Tests for Pancytopenia

Genetic tests related to Pancytopenia:

# Genetic test Affiliating Genes
1 Pancytopenia 29

Anatomical Context for Pancytopenia

MalaCards organs/tissues related to Pancytopenia:

40
Bone, Bone Marrow, T Cells, Myeloid, Liver, B Cells, Lung

Publications for Pancytopenia

Articles related to Pancytopenia:

(show top 50) (show all 6928)
# Title Authors PMID Year
1
Perioperative management for a patient with chronic pancytopenia: a case of aplastic anemia with persistent neutropenia following preoperative administration of G-CSF. 54 61
20094735 2010
2
[Intravascular large B-cell lymphoma with pontine involvement successfully treated with R-hyper-CVAD/R-MTX-Ara-C regimen]. 61 54
20379108 2010
3
Massive ascites associated with all-trans retinoic acid treatment in therapy-related acute promyelocytic leukemia. 61 54
20190483 2010
4
Development of thrombopoietin receptor agonists for clinical use. 61 54
19630808 2009
5
Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status. 54 61
19037596 2009
6
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. 61 54
18541787 2008
7
Paradoxical elevated thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age. 61 54
18520612 2008
8
Acute colchicine intoxication in a child: a case report. 61 54
17505274 2007
9
[Asian variant of intravascular large B-cell lymphoma diagnosed by bone marrow biopsy]. 61 54
17313078 2007
10
Donor-type myelodysplastic syndrome with t(2;3) and monosomy 7 after allogeneic peripheral blood stem cell transplantation and liver transplantation in a patient with severe-type aplastic anemia. 54 61
17118765 2006
11
Two cases of thiopurine methyltransferase (TPMT) deficiency--a lucky save and a near miss with azathioprine. 61 54
16995868 2006
12
MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. 61 54
16470591 2006
13
Thrombopoietin regulates differentiation of rhesus monkey embryonic stem cells to hematopoietic cells. 54 61
15958695 2005
14
[CD5- CD11c+ CD23- small lymphocytic lymphoma evolving from aplastic anemia]. 54 61
15387287 2004
15
[Spontaneous recovery from pancytopenia in a young female patient with paroxysmal nocturnal hemoglobinuria(PNH): changes in the GPI-anchor expression on peripheral blood cells]. 61 54
15103939 2004
16
Refractory chronic GVHD emerging after splenectomy in a marrow transplant recipient with accelerated phase CML. 54 61
12858207 2003
17
Co-administration of Flt-3 ligand counteracts the actions of thrombopoietin in myelosuppressed rhesus monkeys. 61 54
12694260 2003
18
Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. 61 54
12477776 2003
19
Adult purpura fulminans associated with staphylococcal infection and administration of colony-stimulating factors. 54 61
12609794 2003
20
Severe pancytopenia from thiopurine methyltransferase deficiency: a preventable complication of 6-mercaptopurine therapy in children with Crohn disease. 61 54
12454589 2002
21
Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. 54 61
12172211 2002
22
Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. 54 61
11895799 2002
23
Girl with combined cellular immunodeficiency, pancytopenia, malformations, deletion 11q23.3 --> qter, and trisomy 8q24.3 --> qter. 54 61
11920839 2002
24
[Successful combined therapy with ATG, cyclosporin and G-CSF for both liver dysfunction and bone marrow failure in hepatitis-associated aplastic anemia]. 61 54
11680980 2001
25
Colchicine induced toxicity and pancytopenia at usual doses and treatment with granulocyte colony-stimulating factor. 61 54
11361215 2001
26
Early onset methotrexate-induced pancytopenia and response to G-CSF: a report of two cases. 54 61
17039083 2001
27
c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. 61 54
11133753 2001
28
One novel and two recurrent missense DKC1 mutations in patients with dyskeratosis congenita (DKC). 54 61
11491307 2001
29
Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inherited thiopurine methyltransferase deficiency. 54 61
11037857 2000
30
[Two cases of intravascular lymphomatosis diagnosed antemortem by transbronchial lung biopsy]. 61 54
10723949 2000
31
Serum thrombopoietin levels in thrombocytopenic and non-thrombocytopenic patients with human immunodeficiency virus (HIV-1) infection. 54 61
10530413 1999
32
Successful cytokine treatment of aplastic anemia following living-related orthotopic liver transplantation for non-A, non-B, non-C hepatitis. 54 61
10081639 1999
33
Recurrent hepatosplenomegaly and peripheral blood cytopenia, persistent Epstein-Barr virus infection and central nervous system manifestation in a patient with lymphadenopathy and low serum uric acid. 54 61
9745782 1998
34
Successful treatment of aplastic anemia with G-CSF and high dose erythropoietin. 61 54
9669693 1998
35
T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia. 54 61
9535034 1998
36
Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients. 54 61
9541479 1998
37
Crescentic glomerulonephritis accompanied by myeloperoxidase-antineutrophil cytoplasmic antibodies in a patient having myelodysplastic syndrome with trisomy 7. 61 54
9469507 1998
38
Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells. 54 61
9293906 1997
39
Growth factor administration following autologous peripheral blood progenitor cell transplantation. 61 54
9373197 1997
40
Prevention of thrombocytopenia by thrombopoietin in myelosuppressed rhesus monkeys accompanied by prominent erythropoietic stimulation and iron depletion. 61 54
9207438 1997
41
Copper deficiency with pancytopenia due to enteral nutrition through jejunostomy. 61 54
16844585 1997
42
Granulocyte-colony stimulating factor in the treatment of colchicine poisoning. 54 61
9154449 1997
43
Treatment of refractory large granular lymphocytic leukemia with 2-chlorodeoxyadenosine. 61 54
9092691 1997
44
[Allopurinol induced pancytopenia in a patient with myeloproliferative disorder]. 61 54
9028164 1997
45
Peripheral blood and bone marrow changes after treatment with ATRA and G-CSF in AML, APL and blast crisis following Vaquez's disease. 61 54
8767533 1996
46
Combination therapy with recombinant human erythropoietin, interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in idiopathic myelofibrosis. 54 61
8701705 1996
47
[The Recormon (recombinant erythropoietin) treatment of a patient with pancytopenia of the blood and chronic viral hepatitis C]. 61 54
9019832 1996
48
Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. 61 54
8552605 1996
49
Trilineage response to granulocyte colony-stimulating factor administration in a patient with myelodysplastic syndrome. 54 61
7545637 1995
50
Early recovery of host-derived hematopoiesis in marrow transplant recipients conditioned with high-dose busulfan and cyclophosphamide. 61 54
7670408 1995

Variations for Pancytopenia

ClinVar genetic disease variations for Pancytopenia:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 DNAJC21 NM_001012339.3(DNAJC21):c.544C>T (p.Arg182Ter)SNV Pathogenic 598950 rs771063992 5:34937536-34937536 5:34937431-34937431
2 CPT2 NM_000098.3(CPT2):c.149C>A (p.Pro50His)SNV Pathogenic 8954 rs28936375 1:53662764-53662764 1:53197092-53197092
3 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
4 FOXP3 NM_014009.3(FOXP3):c.1190G>A (p.Arg397Gln)SNV Pathogenic 379222 rs1057520529 X:49107901-49107901 X:49251440-49251440
5 TTR NM_000371.4(TTR):c.424G>A (p.Val142Ile)SNV Pathogenic/Likely pathogenic 13426 rs76992529 18:29178618-29178618 18:31598655-31598655
6 RUNX1 NM_001754.4(RUNX1):c.502G>T (p.Gly168Ter)SNV Likely pathogenic 627081 21:36252860-36252860 21:34880563-34880563
7 SOX3 NM_005634.2(SOX3):c.735_737dup (p.Ala248dup)duplication Conflicting interpretations of pathogenicity 95305 rs398124211 X:139586488-139586489 X:140504323-140504324

Expression for Pancytopenia

Search GEO for disease gene expression data for Pancytopenia.

Pathways for Pancytopenia

Pathways related to Pancytopenia according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.2 THPO MPL IFNG EPO CSF3 CSF2
2
Show member pathways
12.14 TP53 IFNG DHFR CSF1
3
Show member pathways
12.01 TP53 THPO TERT IFNG DKC1
4 11.72 IFNG CSF2 CSF1
5
Show member pathways
11.71 FOXP3 CSF3 CSF2
6 11.64 TP53 IFNG CSF2
7
Show member pathways
11.59 IFNG FOXP3 CSF2
8 11.57 IFNG CSF2 CSF1
9 11.55 THPO EPO CSF3 CSF2 CSF1
10 11.49 TERT IFNG DKC1
11 11.47 TERT EPO CP
12 11.43 TERT CSF3 CSF2
13 11.3 CSF3 CSF2 CSF1
14 11.24 EPO CSF3 CSF2 CSF1
15 11.23 THPO MPL IFNG EPO CSF3 CSF2
16
Show member pathways
11.1 IFNG FOXP3 CSF2
17 10.72 IFNG CSF3 CSF2 CSF1
18 10.67 CSF2 CSF1

GO Terms for Pancytopenia

Cellular components related to Pancytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 TTR THPO IFNG EPO CSF3 CSF2

Biological processes related to Pancytopenia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.85 TP53 IFNG FOXP3 CSF2 CSF1
2 positive regulation of cell proliferation GO:0008284 9.63 THPO IFNG EPO CSF3 CSF2 CSF1
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.58 IFNG EPO CSF2
4 negative regulation of neuron death GO:1901215 9.54 EPO CSF3 CSF1
5 negative regulation of interleukin-17 production GO:0032700 9.49 IFNG FOXP3
6 replicative senescence GO:0090399 9.48 TP53 TERT
7 response to salt stress GO:0009651 9.43 TP53 EPO
8 cytokine-mediated signaling pathway GO:0019221 9.35 TP53 MPL CSF3 CSF2 CSF1
9 thrombopoietin-mediated signaling pathway GO:0038163 9.32 THPO MPL
10 positive regulation of interleukin-23 production GO:0032747 9.26 IFNG CSF2
11 macrophage differentiation GO:0030225 8.8 IFNG CSF2 CSF1

Molecular functions related to Pancytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chaperone binding GO:0051087 9.43 TP53 TERT CP
2 growth factor activity GO:0008083 9.26 THPO CSF3 CSF2 CSF1
3 telomerase activity GO:0003720 9.16 TERT DKC1
4 cytokine activity GO:0005125 9.1 THPO IFNG EPO CSF3 CSF2 CSF1

Sources for Pancytopenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....